JB Chemicals & Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 506943 | NSE: JBCHEPHARM | Pharmaceuticals & Drugs | Small Cap

JB Chem & Pharma Share Price

1,746.95 28.40 1.65%
as on 12-Jul'24 16:01

DeciZen - make an informed investing decision on JB Chem & Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation


3. Price Trend

Semi Strong

JB Chemicals & Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (SA):
Market Cap:
27,131.2 Cr.
52-wk low:
52-wk high:

Is JB Chemicals & Pharmaceuticals Ltd an attractive stock to invest in?

1. Is JB Chemicals & Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that JB Chemicals & Pharmaceuticals Ltd is a good quality company.

2. Is JB Chemicals & Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of JB Chemicals & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is JB Chemicals & Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of JB Chemicals & Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of JB Chem & Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
JB Chemicals & Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 9.6%10.2%12.4%10.6%7.5%11.7%17.4%24.5%17.1%16.4%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 9571,0611,1651,1991,2551,5011,6411,8922,1902,8843,299
Sales YoY Gr.-11%9.8%2.9%4.7%19.6%9.3%15.3%15.7%31.7%-
YoY Gr.-8.9%35.2%-1.6%-26.4%68.5%55.6%55.3%-16.4%17.4%-
BVPS (₹) 61.859.972.181.88792.593.5116.9132.1150186
Adj Net
Cash Flow from Ops. -11.7143171178116193272335147629-
Debt/CF from Ops. -80.710.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.1%18.1%20.7%31.7%
Adj EPS 17.5%31.9%15.1%17.4%
Share Price 36.6% 56.2% 24.1% 38.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 20.80%

Sales growth is growing at healthy rate in last 3 years 20.69%

Net Profit is growing at healthy rate in last 3 years 15.10%

Sales growth is good in last 4 quarters at 14.41%

No data to display

Latest Financials - JB Chemicals & Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 35 35.6
TTM Sales (₹ Cr.) 3,299 3,484
BVPS (₹.) 186 188.3
Reserves (₹ Cr.) 2,871 2,908
P/BV 9.40 9.28
PE 49.93 49.09
From the Market
52 Week Low / High (₹) 1185.00 / 1935.00
All Time Low / High (₹) 2.70 / 1935.00
Market Cap (₹ Cr.) 27,131
Equity (₹ Cr.) 15.5
Face Value (₹) 1
Industry PE 43.9

Management X-Ray of JB Chem & Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of JB Chem & Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 8028689399801,0731,2131,2721,3401,6812,219
Manufacturing Costs249276175178189203191197248292
Material Costs2813234704694845365696267441,037
Employee Cost 132147166188217258294306399500
Other Costs 141122129145182215219211290391
Operating Profit 154193226219182288368552509665
Operating Profit Margin (%) 16.1%18.2%19.4%18.2%14.5%19.2%22.4%29.2%23.2%23.0%
Other Income 38105650564050116399
Interest 671053537534
Depreciation 273840465655656771112
Exceptional Items -6500000-10000
Profit Before Tax 94159231217179269340594471527
Tax 26465144518771147110138
Profit After Tax 68114179173128182268447361389
PAT Margin (%) 7.2%10.7%15.4%14.4%10.2%12.1%16.3%23.6%16.5%13.5%
Adjusted EPS (₹)4.06.710.610.27.711.417.428.923.425.1
Dividend Payout Ratio (%)37%105%24%5%13%22%32%29%35%35%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 1,0481,0161,2231,3881,4531,4851,4451,8062,0412,321
Share Capital 17171717171615151515
Reserves 1,0319991,2061,3711,4371,4691,4301,7912,0262,305
Minority Interest0000000000
Long Term Debt000000000383
Short Term Debt811051744928262926267
Trade Payables52626979100111152164196222
Others Liabilities 1612655395816467053855427351,083
Total Liabilities 1,3421,4492,0052,0972,2282,3272,0122,5392,9994,015

Fixed Assets

Gross Block5115726809649801,0121,1051,1081,7972,522
Accumulated Depreciation229271310355410460522544593701
Net Fixed Assets2823013696095705525835651,2041,822
CWIP 46551354171516261955
Investments 536597612544567589536811146339
Trade Receivables248248266265301300344374518524
Cash Equivalents 119117152112264056
Others Assets107109479508583641289458723833
Total Assets 1,3421,4492,0052,0972,2282,3272,0122,5392,9994,015

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity -12143171178116193272335147629
PBT 94159231217179269340594471527
Adjustment 1436-1010152715-5697203
Changes in Working Capital -93-141-0-40-424-61-294-13
Tax Paid -27-38-51-49-38-61-87-140-127-89
Cash Flow From Investing Activity -139-122-52-42-24-2824-2314-956
Capex -57-70-189-153-29-41-691-697-757
Net Investments -84-5311710931091-233700-186
Others 2119213211-13
Cash Flow From Financing Activity 12-23-97-165-59-156-305-87-138343
Net Proceeds from Shares 0100000008
Net Proceeds from Borrowing 000000000521
Interest Paid -3-4-2-3-3-4-2-6-2-31
Dividend Paid -30-30-188-6-10-21-141-73-128-128
Others 451092-156-46-131-163-7-8-28
Net Cash Flow -138-222-30329-10181316
ROE (%)6.6511.0116.0113.259.0112.3918.327.518.7717.83
ROCE (%)9.0914.6519.1315.6512.518.322.9636.3324.0422.02
Asset Turnover Ratio0.740.770.670.580.580.660.760.830.810.85
PAT to CFO Conversion(x)-
Working Capital Days
Receivable Days83848181827372697364
Inventory Days38414145494749495145
Payable Days67645157687284928874

JB Chemicals & Pharmaceuticals Ltd Stock News

JB Chemicals & Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of JB Chem & Pharma on 12-Jul-2024 16:01 is ₹1,747.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Jul-2024 16:01 the market cap of JB Chem & Pharma stood at ₹27,131.2.
The latest P/E ratio of JB Chem & Pharma as of 12-Jul-2024 16:01 is 49.93.
The latest P/B ratio of JB Chem & Pharma as of 12-Jul-2024 16:01 is 9.40.
The 52-week high of JB Chem & Pharma is ₹1,935 and the 52-week low is ₹1,185.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of JB Chem & Pharma is ₹3,299 ( Cr.) .

About JB Chemicals & Pharmaceuticals Ltd

Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.

JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.

JBCPL exports too many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets such as USA, Europe and Australia. JBCPL has a strong R&D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its state-of-the-art manufacturing facilities are approved by health authorities of key regulated markets.

Business area of the company

J. B. Chemicals & Pharmaceuticals is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and APIs.

Milestones & awards


  • Shri. Dinesh Mody, Director, JBCPL, receiving the Prestigious National Export Award/Trophy for the year 1996-97, from the Hon’ble Prime Minister of India, Shri. Atal Behari Vajpayee


  • J. B. Chemical & Pharmaceuticals Ltd. is honoured with the IDMA Quality Excellence Award: ‘Certificate of Merit’ for distinction in quality manufacturing at its manufacturing unit in Panoli.


  • Company awarded a Golden Status certificate by the Govt. of India.


  • J.B. Chemical & Pharmaceuticals Ltd. receives CHEMEXCIL’s ‘First Award’ for Outstanding Export Performance of Pharmaceuticals in the large-scale manufacturer’s category. Received South Africa MCA approval for its tablets facility at Panoli.


  • First ANDA filing with USFDA for Ciprofloxacin.
  • First company to market Rantac CD.
  • Approval from Columbian Drug Regulatory Authority INVIMA for its state-of-the-art facility at Panoli.


  • Features in the Forbes Global list 100 for “Best under $1 Billion” in Asia-Pacific.
  • Receives its maiden USFDA approval to market Ciprofloxacin tablets in the US market.
  • UKMHRA approves JBCPL’s tablet manufacturing facility at Panoli.


  • TGA Australia approves JBCPL’s tablet manufacturing facilities at Panoli, Gujarat, India.
  • JBCPL receives USFDA approval to market Fluconazole tablets in the US market.
  • JBCPL features in Forbes Asia Pacific 200 List for “Best under a Billion” for second year in a row.


  • The ‘Niryat Shree’ Certificate of Excellence was awarded to Unique Pharmaceutical Laboratories Limited, a division of JBCPL, by the Federation of Indian Export Organisations (FIEO) for outstanding export performance in the category of Chemicals, Drugs, Pharma & Allied Products, Non-SSI for the year 2004-05.


  • JBCPL’s Annual Report for the year ended March 31, 2005 was awarded a merit certificate by the South Asian Federation of Accountants (SAFA), an apex body of SAARC, for the Best Presented Accounts for the year 2005 in the category of “Hospitality, Health, Transport, Shipping, etc.’


  • Made a strategic investment in a company in South Africa called Biotech Laboratories.


  • Divested the OTC portfolio in Russia, Ukraine and CIS to J&J.


  •  Resignation of a director - Dr. Niranjan Maniar due to health problem.


  • Shri J. B. Mody, Chairman, receives Lifetime Achievement Award.
  • Mr. J. B. Mody’s Lifetime Achievement Award AV on 13-11-2017.


  • US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg. and 10 mg. (for treatment of orthostatic hypotension).


  • This is to inform you that US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.